Sri Gayathri Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.25 Cr
as on 24-10-2024
- Company Age 25 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.69 Cr
as on 24-10-2024
- Satisfied Charges ₹ 1.66 Cr
as on 24-10-2024
- Revenue -9.21%
(FY 2023)
- Profit -51.88%
(FY 2023)
- Ebitda 15.50%
(FY 2023)
- Net Worth 5.51%
(FY 2023)
- Total Assets 17.77%
(FY 2023)
About Sri Gayathri Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹6.69 Cr. The company has closed loans amounting to ₹1.66 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sivaramakrishna Alla, Hemalatha Alla, and Kovvuri Reddy serve as directors at the Company.
- CIN/LLPIN
U24230TG1999PTC031720
- Company No.
031720
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sri Gayathri Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sivaramakrishna Alla  | Managing Director | 09-Oct-2008 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hemalatha Alla | Director | 03-Jun-2011 | Current |
| Kovvuri Reddy | Additional Director | 04-Mar-2024 | Current |
Financial Performance of Sri Gayathri Drugs.
Sri Gayathri Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.21% decrease. The company also saw a substantial fall in profitability, with a 51.88% decrease in profit. The company's net worth moved up by a moderate rise of 5.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Gayathri Drugs?
In 2023, Sri Gayathri Drugs had a promoter holding of 92.16% and a public holding of 7.84%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹6.69 Cr
₹1.66 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 6.69 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2021 | Axis Bank Limited | ₹5.00 M | Open |
| 30 Dec 2020 | Axis Bank Limited | ₹0.40 M | Open |
| 13 Oct 2006 | Axis Bank Limited | ₹6.15 Cr | Open |
| 26 Nov 2005 | State Bank Of India | ₹0.90 M | Satisfied |
| 10 Jan 2000 | State Bank Of India | ₹0.60 M | Satisfied |
How Many Employees Work at Sri Gayathri Drugs?
Sri Gayathri Drugs has a workforce of 8 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Gayathri Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Gayathri Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
